Form 8-K - Current report:
SEC Accession No. 0000950170-25-084279
Filing Date
2025-06-10
Accepted
2025-06-10 16:00:08
Documents
12
Period of Report
2025-06-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cue-20250604.htm   iXBRL 8-K 123836
2 CERT OF AMENDMENT cue-ex3_1.htm EX-3.1 13423
3 SIP PLAN 2025 cue-ex99_1.htm EX-99.1 196595
  Complete submission text file 0000950170-25-084279.txt   504868

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cue-20250604.xsd EX-101.SCH 46338
14 EXTRACTED XBRL INSTANCE DOCUMENT cue-20250604_htm.xml XML 4692
Mailing Address 40 GUEST STREET BOSTON MA 02135
Business Address 40 GUEST STREET BOSTON MA 02135 617-949-2680
Cue Biopharma, Inc. (Filer) CIK: 0001645460 (see all company filings)

EIN.: 473324577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38327 | Film No.: 251036993
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)